Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

This trial is testing a combination of two targeted antibody therapies (KN026 and KN046) with or without chemotherapy (XELOX) for people with HER2-positive stomach cancer or cancer of the gastroesophageal junction (where the esophagus meets the stomach) that is locally advanced but has not spread to distant organs. HER2-positive means the cancer cells have too many copies of a protein that helps cancer grow. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed locally advanced HER2-positive stomach or gastroesophageal junction cancer - Your heart is functioning well (ejection fraction of 50% or higher) - Your blood counts, kidney, and liver levels are within acceptable ranges - You have a life expectancy of more than 3 months **You may NOT be eligible if...** - You have had another active cancer in the past 5 years - You have HIV infection, active tuberculosis, or lung disease - You have a serious heart condition (e.g., recent heart attack or severe heart failure) - You have previously received immunotherapy drugs like PD-1 or CTLA-4 inhibitors Talk to your doctor to see if this trial is right for you.